Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. The study aims to assess the safety, tolerability, and effectiveness of REGN5381 in patients suffering from heart failure with reduced ejection fraction.
The intervention being tested is REGN5381, an experimental drug administered as a single dose intravenous infusion. It is designed to improve heart function in patients with chronic heart failure.
The study employs a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on April 11, 2024, with the primary completion and estimated completion dates yet to be announced. The most recent update was submitted on July 18, 2025, indicating ongoing recruitment.
This study could significantly impact Regeneron’s stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the heart failure treatment market. Investors should monitor updates closely for potential market shifts.
The study is currently ongoing, with further details available on the ClinicalTrials portal.